^
BIOMARKER:

ALK rearrangement

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
ALK rearrangement
Non Small Cell Lung Cancer
alectinib
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
alectinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Adenocarcinoma
crizotinib
Resistant
:
C4
Exp Ther Med - 3 weeks - (New C4)
ALK rearrangement
Non Small Cell Lung Cancer
crizotinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ALK inhibitor
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
ceritinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
lorlatinib
Sensitive
:
A2
ALK rearrangement
Non Small Cell Lung Cancer
brigatinib
Sensitive
:
A2
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
ceritinib
Sensitive
:
B
ALK rearrangement
Non Small Cell Lung Cancer
nivolumab
Sensitive
:
C2
ALK rearrangement
Solid Tumor
alectinib
Sensitive
:
C2
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
crizotinib
Sensitive
:
C2
ALK rearrangement
Non Small Cell Lung Cancer
bevacizumab + alectinib
Sensitive
:
C2
ALK rearrangement
Non Small Cell Lung Cancer
ceritinib + ribociclib
Sensitive
:
C2
ALK rearrangement
Non Small Cell Lung Cancer
durvalumab
Sensitive
:
C2
ALK rearrangement
Non Small Cell Lung Cancer
bevacizumab + crizotinib
Sensitive
:
C3
ALK rearrangement
Lung Adenocarcinoma
Tyrosine kinase inhibitor
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
PD-L1 inhibitor
Resistant
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
Tyrosine kinase inhibitor
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ALK rearrangement
Non-Hodgkin’s Lymphoma
ceritinib
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
IPI-504
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
ipilimumab
Sensitive
:
C3
ALK rearrangement
Lung Non-Small Cell Squamous Cancer
ALK inhibitor
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
WX-0593
Sensitive
:
C3
ALK rearrangement
Non Small Cell Lung Cancer
rivoceranib + camrelizumab
Sensitive
:
C3
ALK rearrangement
Renal Cell Carcinoma
crizotinib
Sensitive
:
C4
ALK rearrangement
Sarcoma
crizotinib
Sensitive
:
C4
ALK rearrangement
Lung Adenocarcinoma
bevacizumab
Sensitive
:
C4
ALK rearrangement
Renal Cell Carcinoma
alectinib
Sensitive
:
C4
ALK rearrangement
Lung Adenocarcinoma
alectinib
Sensitive
:
C4
ALK rearrangement
Lung Cancer
BMS-722782
Sensitive
:
D
ALK rearrangement
Small Cell Lung Cancer
alectinib
Sensitive
:
D
ALK rearrangement
Lung Cancer
alectinib + YHO-1701
Sensitive
:
D